![Stefan W. Henning](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stefan W. Henning
Keine laufenden Positionen mehr
Karriereverlauf von Stefan W. Henning
Ehemalige bekannte Positionen von Stefan W. Henning
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Xerion Pharmaceuticals AG
![]() Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Xerion Pharmaceuticals GmbH develops antibodies and therapeutic targets. It uniquely focuses on proteins, using proprietary technologies to selectively block their function in diseased cells thereby mimicking the activity of a drug. The company is headquartered in Munich, Germany. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2005 | - |
Ausbildung von Stefan W. Henning
Eberhard Karls Universität Tübingen | Doctorate Degree |
Statistik
International
Deutschland | 4 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Avontec GmbH
![]() Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Xerion Pharmaceuticals AG
![]() Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Xerion Pharmaceuticals GmbH develops antibodies and therapeutic targets. It uniquely focuses on proteins, using proprietary technologies to selectively block their function in diseased cells thereby mimicking the activity of a drug. The company is headquartered in Munich, Germany. | Health Technology |
- Börse
- Insiders
- Stefan W. Henning
- Erfahrung